BURKOŇ, Petr, Jan TRNA, Marek SLÁVIK, Radim NĚMEČEK, Tomáš KAZDA, Petr POSPÍŠIL, Milan DASTYCH, Michal EID, Ivo NOVOTNY, Tomáš PROCHÁZKA and Miroslav VRZAL. Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration. Biomedicines. Basel: MDPI, 2022, vol. 10, No 10, p. 1-23. ISSN 2227-9059. Available from: https://dx.doi.org/10.3390/biomedicines10102480.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer-A Critical Review and Practical Consideration
Authors BURKOŇ, Petr (203 Czech Republic, belonging to the institution), Jan TRNA (203 Czech Republic, guarantor, belonging to the institution), Marek SLÁVIK (703 Slovakia, belonging to the institution), Radim NĚMEČEK (203 Czech Republic, belonging to the institution), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Petr POSPÍŠIL (203 Czech Republic, belonging to the institution), Milan DASTYCH (203 Czech Republic, belonging to the institution), Michal EID (203 Czech Republic, belonging to the institution), Ivo NOVOTNY (203 Czech Republic), Tomáš PROCHÁZKA (203 Czech Republic, belonging to the institution) and Miroslav VRZAL (203 Czech Republic).
Edition Biomedicines, Basel, MDPI, 2022, 2227-9059.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.700
RIV identification code RIV/00216224:14110/22:00127201
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/biomedicines10102480
UT WoS 000872249300001
Keywords in English pancreatic neoplasms; neoadjuvant therapy; stereotactic body radiotherapy; review
Tags 14110212, 14110213, 14110811, 14110812, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 5/4/2023 13:51.
Abstract
Pancreatic cancer is the third leading cause of cancer death in the developed world and is predicted to become the second by 2030. A cure may be achieved only with surgical resection of an early diagnosed disease. Surgery for more advanced disease is challenging and can be contraindicated for many reasons. Neoadjuvant therapy may improve the probability of achieving R0 resection. It consists of systemic treatment followed by radiation therapy applied concurrently or sequentially with cytostatics. A novel approach to irradiation, stereotactic body radiotherapy (SBRT), has the potential to improve treatment results. SBRT can deliver higher doses of radiation to the tumor in only a few treatment fractions. It has attracted significant interest for pancreatic cancer patients, as it is completed quickly, requires less time away from full-dose chemotherapy, and is well-tolerated than conventional radiotherapy. In this review, we aim to provide the reader with a basic overview of current evidence for SBRT indications in the treatment of pancreatic tumors. In the second part of the review, we focus on practical information with respect to SBRT treatment plan preparation the performance of such therapy. Finally, we discuss future directions related to the use of magnetic resonance linear accelerators.
Links
90125, large research infrastructuresName: BBMRI-CZ III
90128, large research infrastructuresName: CZECRIN III
PrintDisplayed: 20/7/2024 12:11